BioXcel Reports Positive OS Results From Phase 2 Trial Of BXCL701 In Patients With SCNC
BioXcel Therapeutics, Inc. (BTAI), a biopharmaceutical company focused on neuroscience and immuno-oncology, announced Tuesday positive overall survival or OS data from its Phase 2 trial of BXCL701 in combination with KEYTRUDA (pembrolizumab) in patients with small cell neuroendocrine prostate cancer or SCNC.
Vincent Oneill Onkosxcel Therapeutics More Such Health News Bioxcel Therapeutics Inc Bioxcel Therapeutics Chief Rd Officer
Source: rttnews.com